A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Proceedings for Annual Meeting of The Japanese Pharmacological Society
Molecular target anticancer drugs have less adverse effects than conventional compounds but often provide patients with unfavorable events. Development of an appropriate administration protocol that alleviate the adverse effects and maximize the desirable effects requires monitoring of drug concentrations in individuals. This strategy is currently inaccessible, owing to no convenient method usable at a clinical site. Furthermore, as for recent drugs whose therapeutic windows remain unevaluated,doi:10.1254/jpssuppl.92.0_1-p-130 fatcat:w37ovj6nzjfxrm5pogemptskau